Diagnostic Reference Levels (DRLs) have been developed for general nuclear medicine, PET and the CT component of hybrid imaging scans. Medical imaging providers are required under the ARPANSA Code of Practice (RPS C-5 Section 3.2.15, previously RPS 14 Section 3.1.8) to regularly compare typical patient doses to the national DRLs to optimise the doses delivered to patients.
Current nuclear medicine diagnostic reference levels
View the current DRLs for nuclear medicine, including planar nuclear medicine, PET and the CT component of SPECT/CT and PET/CT procedures.
Nuclear medicine survey
ARPANSA is not currently conducting an ongoing nuclear medicine survey. However, to help facilities conduct local dose audits, we have created a nuclear medicine DRL template, downloadable from the link below:
The spreadsheet is intended for dose audits of the CT component of multimodality imaging and for the administration of radioisotopes where the amount of radiopharmaceutical delivered is varied depending on body habitus (for example via weight or BMI).
Nuclear medicine statistics
View summary statistics relating to the data submitted to APRANSA’s 2022 nuclear medicine survey and see how those data were used to derive the current DRLs. The tables on this page can provide valuable insight into how you compare to the Australian nuclear medicine community.
Nuclear medicine DRLs in more detail
Find out more about the nuclear medicine/PET DRLs, including information relating to the regulatory requirements and details on how to conduct a local dose comparison.
Superseded Australian diagnostic reference levels for nuclear medicine
View the superseded nuclear medicine diagnostic reference levels and the associated DRL comparison spreadsheet template.
